Brenntag and dsm-firmenich Partnered on Vitamin Supply
Bioprocessing firms can now access GMP-grade vitamins for cell culture through an expanded global distribution agreement.
Updated on Oct. 4, 2026 in Consumer Goods
Live Poll
Do you believe partnerships between large global companies generally benefit consumers in the long run?
Brenntag and dsm-firmenich have formed a global partnership to distribute high-purity vitamins under the new co-brand BYPHAR powered by Biond. The deal covers eight distinct products intended for upstream bioprocessing in the biologics, vaccine, and cell therapy sectors.
Why it matters
Securing reliable access to GMP-grade materials is critical for operators in the life sciences space to maintain compliance and consistency in bioprocessing workflows. This partnership formalizes a long-standing supply chain link between these two entities across six major regions.
The new BYPHAR powered by Biond co-brand features eight products that are now available in multiple pack sizes across six global regions. This collaboration formalizes a 30-year existing professional relationship between the two companies.
The players
Brenntag
A global chemical and ingredients distributor that serves a wide range of industrial and life sciences markets.
dsm-firmenich
A global innovator in nutrition, health, and beauty that produces specialized ingredients for food and pharmaceutical applications.
The details
The agreement grants Brenntag exclusive distribution rights for dsm-firmenich's Biond portfolio of high-purity vitamins across North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific. These vitamins are engineered for use in cell culture and feed media, supporting upstream processes for vaccines and biologics. Businesses in these segments should evaluate how this consolidated distribution channel impacts their current procurement and supply chain logistics.
Timeline
October 4, 2026: The partnership agreement was publicly announced.
Market Landscape
This partnership follows the established industry trend toward specialized GMP-grade supply chain consolidation in bioprocessing by centralizing access to critical cell culture inputs. It marks a formalization of long-term supplier relationships to ensure consistency in complex regulatory environments.
Operators in bioprocessing should audit their current vitamin procurement to determine if this new distribution channel offers better logistics or scaling options. Assess whether your current supply chain reliability for high-purity cell culture inputs meets upcoming production volume requirements.
The takeaway
The move underscores the growing need for simplified, exclusive access to high-purity materials in the highly regulated bioprocessing market. Operators should track whether this co-branding effort improves lead times for their own supply chains compared to previously fragmented sourcing methods.
Further reading
For more on managing supply chain shifts, see our Consumer Goods section.
Source note: This article includes information reported by Pharmafile.
Live Poll
Do you believe partnerships between large global companies generally benefit consumers in the long run?
